Quantcast

Latest International AIDS Vaccine Initiative Stories

2011-02-07 05:00:00

LOS ANGELES, Feb. 7, 2011 /PRNewswire/ -- The Black AIDS Institute ("BAI"), the only national HIV/AIDS think tank focused exclusively on the Black community in the US, today released its 2011 State of AIDS in Black America report, Deciding Moment. 2011 marks the 30th anniversary of the AIDS epidemic in America and presents unique opportunities to curtail the HIV/AIDS pandemic, but key challenges remain to moving forward in the AIDS response in Black America. The report opens with an...

2011-01-20 07:00:00

ATLANTA, Jan. 20, 2011 /PRNewswire/ -- Harriet L. Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, Inc. (OTCQB/OTC Bulletin Board: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, is one of three recipients of the 2011 Georgia Bio (GaBio) Community Awards. Dr. Robinson will be honored at the GaBio Annual Awards Dinner to be held Thursday, January 20 at Atlanta's Fox Theater. Dr. Robinson is the developer of GeoVax's HIV-1 AIDS...

2010-12-08 03:19:00

SINGAPORE, Dec. 8, 2010 /PRNewswire-Asia/ -- From the 1st to the 3rd of March 2011, vaccine leaders from developing and developed world will meet at Vaccine World Summit in New Delhi. The event will be hosted by IMAPAC, in partnership with DCVMN (Developing Countries Vaccine Manufacturers Network). Participants will be discussing strategies to tackle global public health challenges including appropriate pandemic surveillance programs, low cost and fast vaccine manufacturing technologies,...

2010-12-06 14:20:00

ATLANTA, Dec. 6, 2010 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) (the "Company"), an Atlanta-based biopharmaceutical company developing human vaccines for HIV/AIDS (HIV-1, Human Immunodeficiency Virus), has appointed David A. Dodd as Chairman of its Board of Directors effective January 1, 2011. Donald G. Hildebrand is stepping down as Chairman and will remain on the board as a Director and continue to serve as a consultant to the Company. Mr. Dodd, age 61, has...

2010-11-29 07:00:00

ATLANTA, Nov. 29, 2010 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for HIV/AIDS (HIV-1, Human Immunodeficiency Virus), announced it was pleased to learn of the partial success observed in the recently completed Phase 2b trial of a therapeutic HIV/AIDS vaccine produced by Bionor Immuno AS of Oslo, Norway. Bionor reported success in reducing viral load (reduction in HIV virus in...

2010-11-16 07:37:00

CHICAGO, Nov. 16, 2010 /PRNewswire/ -- VaxTrac announced today that it has received a US$100,000 Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation. The grant will support an innovative global health research project conducted by Mark Thomas, Executive Director, titled "VaxTrac Pilot Program 1 Narnaul, India." VaxTrac's project is one of 65 grants announced by the Gates Foundation in the fifth funding round of Grand Challenges Explorations, an initiative to...

2010-11-09 08:00:00

ATLANTA, Nov. 9, 2010 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTCQB / OTC Bulletin Board: GOVX), an Atlanta-based biopharmaceutical firm (the "Company" or "GeoVax") developing vaccines that prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced its financial results for the three and nine months ended September 30, 2010. GeoVax reported a net loss of $644,666 ($0.04 per share) for the three months ended September 30, 2010, compared to $230,815 ($0.02 per...

2010-11-04 08:27:00

ATLANTA, Nov. 4, 2010 /PRNewswire/ -- GeoVax Labs, Inc. (OTCQB/OTC Bulletin Board: GOVX), an Atlanta-based, biopharmaceutical firm dedicated to developing vaccines that prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced that it has been awarded a grant of $244,500 related to its HIV/AIDS vaccine development activities under the Qualifying Therapeutic Discovery Project ("QTDP") program. GeoVax received the maximum level allowable under the program based on the...

2010-10-18 06:30:00

ATLANTA, Oct. 18 /PRNewswire/ -- Robert T. McNally, Ph.D., president and CEO of GeoVax Labs, Inc. (OTCQB/OTC Bulletin Board: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, has contributed an article on the search for an HIV vaccine to the October 15 issue of Genetic Engineering & Biotechnology News (GEN). In the article, titled "Search for Effective HIV Vaccine Intensifies: Progress to Date Result of Robust Funding and Cooperation...

2010-10-17 20:10:00

SHANGHAI, Oct. 17 /PRNewswire-Asia/ -- At the end of 2009, the vaccine industry raised so much concern worldwide that the headlines of the business media were occupied by various kinds of news about vaccine enterprises. For example, Sinovac Biotech Co., Ltd. successfully landed on the Nasdaq, then Simcere, a pharmaceutical company based in Jiangsu Province, listed on the NYSE, announced a 50.8% stake in Ealong Biotech and took control of the latter, and finally Novartis, the world-famous...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.